|
在网上看到一则消息,也是其他网友推荐的一个股票SVNT,不知老大有何建议,可否买此股票?多谢
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that its biologics license application (BLA) for KRYSTEXXA(TM) (pegloticase), a novel biological drug for treatment failure gout (TFG) patients, will be reviewed by the Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration (FDA) on June 16, 2009.
PDUFA date of August 1, 2009.
还有我持有PARD,3.60买的,不知道何时可卖?多谢。 |
|